Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337907 · ClinicalTrials.gov registry record · Phase 2
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 329
- Enrollment target
NCT02337907 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 329 participants.
The verdict
NCT02337907, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 329 participants
- Enrollment target
Study Summary
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
Interventions
- DRUG Placebo
- DRUG Donepezil
- DRUG BI 409306
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2017-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02337907
The ClinicalTrials.gov registry entry for NCT02337907 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02337907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02337907 about?
NCT02337907 is a clinical study titled "BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.". The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
What is the current status of trial NCT02337907?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 329 participants. The study started on 2015-01-21. Estimated completion is 2017-10-10.
What interventions are being tested in trial NCT02337907?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG), BI 409306 (DRUG).
Who is sponsoring clinical trial NCT02337907?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.